Multiple Myeloma Posts on Medivizor

Evaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.

Posted by Medivizor on Feb 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study compared a combination therapy of carfilzomib (Kyprolis), lenalidomide (Revlimid), dexamethasone (Decadron), and cyclophosphamide (Cytoxan) to control combination therapies as an alternative treatment regimen in newly diagnosed patients with multiple myeloma (MM). The authors concluded that this regimen provided very good...

Improved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.

$Improved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.$

Posted by Medivizor on Feb 27, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effect of daratumumab (Darzalex)-based treatments on sustained minimal residual disease (MRD) negativity and outcomes in patients with relapsed/refractory (RR) multiple myeloma (MM). The data showed that treatments including daratumumab led to sustained MRD negativity and improved outcomes in these...

How do bortezomib, thalidomide, dexamethasone and daratumumab impact the quality of life of patients with multiple myeloma?

Posted by Medivizor on Feb 26, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the health-related quality of life of patients with multiple myeloma (MM) after treatment with VTd (bortezomib, thalidomide, and dexamethasone) with or without daratumumab (D; Darzalex). The study found that all patients that received treatment had an improved quality of life, while...

Long-term follow-up after bortezomib, thalidomide, and dexamethasone treatment followed by double stem cell transplant in patients with multiple myeloma.

Posted by Medivizor on Feb 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study compared long-term outcomes after treatment with bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (Ozurdex) or VTD compared to thalidomide and dexamethasone (TD) followed by double hematopoietic stem cell transplant (HSCT) in patients with newly diagnosed multiple myeloma (MM). The study found...

Can low body mass index and undernutrition influence survival in patients with multiple myeloma?

Posted by Medivizor on Feb 14, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the impact of low body mass index (BMI; a measure of weight in relation to height) and undernutrition in patients with multiple myeloma (MM). The authors concluded that being underweight, low protein level higher high lactate dehydrogenase (LDH) and light chain ratios, and poor performance status were...

Comparing two ways of collecting stem cells to improve treatment of multiple myeloma

Posted by Medivizor on Feb 7, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study looked at two different ways of getting stem cells from the blood to improve the treatment of patients with multiple myeloma (MM). This study showed that the use of cyclophosphamide (CTX; Cytoxan) with granulocyte-colony stimulating factor (G-CSF; Neupogen) had the best outcomes. Some background MM is the second...

Clinical guidelines for the treatment of multiple myeloma.

Posted by Medivizor on Feb 7, 2021 in Multiple Myeloma | 0 comments

In a nutshell This article reviewed current treatment options for treating multiple myeloma (MM). Some background MM is a form of cancer that originates from plasma cells (a form of white blood cell). This usually results in other normal cells of the bone marrow not working properly. MM is usually diagnosed in older patients. Despite...

Do statins reduce mortality in multiple myeloma?

Posted by Medivizor on Jan 31, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study looked at the effect statins had on the outcomes of patients with multiple myeloma (MM). The authors found that the use of statins is likely associated with lower mortality in these patients. Some background MM is a form of cancer that originates from plasma cells (a form of white blood cell). This usually results...

Looking for patients with relapsed or refractory multiple myeloma to trial a treatment combination

$Looking for patients with relapsed or refractory multiple myeloma to trial a treatment combination$

Posted by Medivizor on Jan 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of combination therapy with venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Ozurdex) with or without bortezomib (Velcade) for unresponsive or relapsed multiple myeloma (MM). The main outcome that is to be measured is the response rate, time to response,...

How does daratumumab with lenalidomide and dexamethasone impact the quality of life of patients with multiple myeloma?

Posted by Medivizor on Dec 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the impact of the D-Rd regimen including daratumumab (Darzalex) combined with lenalidomide (Revlimid) and dexamethasone (Decadron) on the quality of life of patients with multiple myeloma (MM) who cannot undergo a transplant. The study showed that patients who received D-Rd reported lower levels of...

What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?

$What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?$

Posted by Medivizor on Dec 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the treatment schedule for panobinostat (Farydak) tablets combines with subcutaneous (injections under the skin) bortezomib (Velcade) and dexamethasone (Ozurdex) tablets in patients with relapsed/refractory (R/R) multiple myeloma (MM). The study found that 20mg of panobinostat should be given twice...

Does age impact the use of autologous hematopoietic cell transplantation for multiple myeloma?

Posted by Medivizor on Dec 25, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study was carried out to examine the effectiveness of autologous stem cell transplant (ASCT) in the management of older patients with multiple myeloma (MM). The authors concluded that ASCT was an effective consolidation therapy in patients with MM across all age groups. Some background MM is a more commonly a cancer of older...

Multiple Myeloma Posts on Medivizor

Evaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.

Improved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.

How do bortezomib, thalidomide, dexamethasone and daratumumab impact the quality of life of patients with multiple myeloma?

Long-term follow-up after bortezomib, thalidomide, and dexamethasone treatment followed by double stem cell transplant in patients with multiple myeloma.

Can low body mass index and undernutrition influence survival in patients with multiple myeloma?

Comparing two ways of collecting stem cells to improve treatment of multiple myeloma

Clinical guidelines for the treatment of multiple myeloma.

Do statins reduce mortality in multiple myeloma?

Looking for patients with relapsed or refractory multiple myeloma to trial a treatment combination

How does daratumumab with lenalidomide and dexamethasone impact the quality of life of patients with multiple myeloma?

What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?

Does age impact the use of autologous hematopoietic cell transplantation for multiple myeloma?

Categories

Recent Posts

Archives

Multiple Myeloma Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email